UK NHS Could Save £4m Annually by Expanding Prosigna Genetic Test to Low‑Risk Breast Cancer Patients An analysis by UCL and Edinburgh researchers suggests that broadening the use of the Prosigna gene‑expression test to all eligible women with low‑risk breast cancer could cut annual NHS costs by £4m, reduce chemotherapy use for over 4,000 patients, and spare thousands from side‑effects. The National Health Service could sidestep an annual expenditure of about four million pounds by extending the availability of a genetic screening tool named Prosigna to women diagnosed with low‑risk breast cancer. The test, which is presently authorised for post‑menopausal women whose tumours have involved no more than three adjacent lymph nodes, evaluates the expression of fifty genes extracted from the primary tumour. A resulting risk score indicates whether the patient can safely rely on hormone therapy alone or whether the disease warrants conventional cytotoxic chemotherapy.Reducing Costs And Side Effects With ProsignaUCL researchers contend that broadening the test's use to include women as young as forty would cut treatment costs by roughly six hundred and fifty‑four pounds per patient and spare more than four thousand women a year from the harsh side effects commonly associated with chemotherapy, such as nausea, vomiting, alopecia, and heightened susceptibility to infection. The findings were unveiled at the European Society of Medical Oncology's annual assembly in Madrid, where Dr Rob Stein highlighted that Prosigna testing can avert chemotherapy for about two thirds of patients with favourable, estrogen‑receptor-positive disease.The study - dubbed OPTIMA - followed 4,429 women aged forty and above whose cancers had metastasised to up to nine lymph nodes or whose tumours measured thirty millimetre or larger. By analysing tissue taken during standard surgical procedures or biopsies, the test generates a score that helps clinicians stratify patients into low‑risk, medium‑risk, or high‑risk categories. In the trial cohort, 67 percent of women fell into the low‑risk bracket and could potentially avoid the standard two‑year course of chemotherapy.Financial analysis by Professor Peter Hall of the University of Edinburgh estimates the cost of the chemotherapy arm of treatment for a new case to be approximately five thousand five hundred pounds over the first two years following diagnosis. This figure encompasses the drugs themselves, nursing care, hospital stays, supportive medications, and hospital readmissions triggered by side‑effect‑related complications.Financial Savings From Avoiding ChemotherapyIn contrast, the Prosigna test, priced at about one thousand nine hundred and fifty‑five pounds per patient in the UK, was shown to reduce the total expenditure by roughly three thousand six hundred and eleven pounds per patient. Once the after‑effects of skipping chemotherapy - such as the early initiation of alternative treatments - were taken into account, the net saving was revised to approximately six hundred and fifty‑four pounds per patient.On a national scale, if the NHS were to administer the test to all eligible women every year, the aggregate annual saving would emerge as roughly four million pounds. Breast cancer remains the most prevalent tumour among women worldwide, with about sixty thousand new invasive cases diagnosed each year in the UK alone. Roughly eighty per cent of these are estrogen‑receptor‑positive, rendering them responsive to endocrine therapy and less dependent on chemotherapy.The growing evidence that many patients receive limited benefit from cytotoxic agents while enduring substantial toxicities has prompted a reassessment of treatment algorithms. The utility of Prosigna as a decision‑making adjunct therefore holds promise for both patient quality of life and the efficient allocation of NHS resources. By integrating genetic risk profiling early in the diagnostic pathway, clinicians can tailor therapy to the individual tumour biology rather than adopting a blanket approach that disproportionately burdens patients and finances.Benefits Of Personalised Medicine For NHSThe broader adoption of Prosigna aligns with the NHS's commitment to personalised medicine and serves as a concrete example of how targeted diagnostics can deliver clinical and economic value. The potential to prevent unnecessary chemotherapy not only enhances patient experience but also liberates clinical capacity and funding for other critical areas of cancer care.Continued research and real‑world evidence will be essential to confirm these estimates and to fine‑tune the criteria for test eligibility, ensuring that the system remains responsive to both medical innovation and fiscal sustainability.